Neurotrophic Keratitis News and Research

RSS
FDA approves first drug for treatment of rare disease affecting the cornea

FDA approves first drug for treatment of rare disease affecting the cornea

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Dompé enters definitive agreement to acquire Anabasis

Dompé enters definitive agreement to acquire Anabasis

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Data from RGN-259 study published in Archives of Ophthalmology

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals proposes common stock public offering